Sat.Jul 10, 2021 - Fri.Jul 16, 2021

Biohaven CEO on migraine drug's fast launch, TikTok ads and battling big pharma

Bio Pharma Dive

Sales of Nurtec ODT during the second quarter were double what Wall Street expected. CEO Vlad Coric explained to BioPharma Dive how the biotech did it, despite being far smaller than its chief rival

Sales 262

Who do you trust? The FDA vs. Pfizer

World of DTC Marketing

SUMMARY: Pfizer says it has data on waning immunity from their COVID vaccine. The FDA and CDC say “not so fast.” ” Booster shots could bring billions in revenue to Pfizer and Moderna. The media is using scare headlines and is not always presenting accurate stories.


Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

USC study shows dire impacts downstream of Nile River dam


Incyte to Report Second Quarter Financial Results

BioTech 365

Incyte to Report Second Quarter Financial Results Incyte to Report Second Quarter Financial Results WILMINGTON, Del.–(BUSINESS –(BUSINESS WIRE)–Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m.


Merck details an immunotherapy 'milestone' in early breast cancer

Bio Pharma Dive

Three months after a rare FDA rejection, Merck has data showing Keytruda can slow the return of triple-negative breast cancer but not, as of yet, proving whether the drug extends lives

Drugs 257

The REAL threats to DTC advertising

World of DTC Marketing

SUMMARY: There is a talent drain at the agency and DTC levels. More experienced DTC people are being forced to retire. TV still gets the biggest share of DTC budgets, but they don’t drive brand objectives. Talented marketers don’t want a career in pharma because of the culture.

HR 220

More Trending

Johnson & Johnson Recalls Sunscreen Because of Benzene Traces

NY Times

The company said it had determined that daily exposure to five Neutrogena and Aveeno sprays would not cause adverse health effects, but recalled the products out of an abundance of caution.

FDA flags rare side effect in new warning on J&J's coronavirus vaccine

Bio Pharma Dive

The agency said the benefits of vaccination with J&J's shot still "clearly outweigh" the risks, which now include very rare cases of a immune-driven condition known as Guillain-Barré

Biogen is in deep trouble and may not survive

World of DTC Marketing

SUMMARY: The Committee on Oversight and Reform and the Committee on Energy and Commerce is investigating the approval process for Biogen’s new Alzheimer’s drug.

Drugs 215

New long-term satellite analysis shows “plum” rainy season wetter now than ever before


New hope for long COVID blood tests after antibody discovery

Pharma Times

Researchers discover presence of 'autoantibodies' in people with persistent COVID-19 symptoms

Major health centers, insurers push back against Aduhelm

Bio Pharma Dive

The Cleveland Clinic and Mount Sinai won't yet administer the controversial Alzheimer's drug, while UnitedHealth's CEO said the insurer would need more time to iron out coverage

Drugs 254

Drug companies know how to play the FDA drug approval process

World of DTC Marketing

SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process.

Drugs 161

Can turmeric reduce joint pain during breast cancer treatment?


UC Davis Comprehensive Cancer Center to study the theory, thanks to $50,000 from Safeway Foundation Credit: UC Davis Health UC Davis Comprehensive Cancer Center received a $50,000 grant from the Safeway Foundation to explore the use of the South Asian spice Turmeric as a way of reducing joint pain in breast cancer patients being treated […].

AI-driven ‘clock’ predicts aging-related illness and mortality

Pharma Phorum

Scientists in the US have developed an artificial intelligence-powered ‘clock’ that can estimate a person’s chance of developing an illness or dying based on the pattern of cytokines in their blood.

Prime Medicine raises $315M to fuel 'search-and-replace' gene editing work

Bio Pharma Dive

Formed around research from the Broad Institute's David Liu and Andrew Anzalone, Prime has attracted significant funding from a wide range of high-profile biotech backers

ACD/Labs, Science Data Experts establish AI partnership

Outsourcing Pharma

The two companies will work together to come up with solutions that use machine learning and artificial intelligence to help accelerate innovation in R&D. Clinical Development

Study finds vaccine hesitancy lower in poorer countries


Digitisation key to improving mental health services in England; report

Pharma Phorum

Faced with a looming mental health crisis, the UK government has been urged to invest in the digitisation of service provision across the NHS in England in a new report from think tank Future Care Capital.

Lilly wagers up to $1B on a biotech's plan for a new type of insulin

Bio Pharma Dive

Rival Novo Nordisk has jumped ahead in developing an injectable drug that responds to changes in blood sugar. An acquisition of Protomer Therapeutics could help Lilly close the gap

Man vs. Machine – Which is Best at Predicting Clinical Trial Outcomes?


A recent Deny-Colton Virtual Salon pitted human intelligence against AI/ML to weigh not just the outcomes, but the process

Future information technologies: Topological materials for ultrafast spintronics


A team led by HZB physicist Dr. Jaime Sánchez-Barriga has gained new insights into the ultrafast response of topological states of matter to femtosecond laser excitation. Credit: HZB/Nature Communication Physics (2021) The laws of quantum physics rule the microcosm.


UK fines drugmakers record £260m for price gouging NHS

Pharma Phorum

The UK’s competition authority has issued its largest ever fine of more than £260 million ($360 million) to several pharma companies accused of colluding to hike the price of medicines delivered to the NHS.

Biogen chases rivals with another bet on emerging class of multiple sclerosis drugs

Bio Pharma Dive

A deal with Innocare gives Biogen a second therapy for MS that targets a protein called BTK, an approach several other competing drugmakers are pursuing, too

NICE to develop guideline for rare blood clots associated with COVID-19 vaccination

Pharma Times

Condition is 'extremely' rare, with only 14.2 cases occurring per million doses of the COVID-19 vaccine

Simplified method for calibrating optical tweezers


Broadband measurement of viscoelasticity with reduced measurement time Credit: Pascal Runde Measurements of biomechanical properties inside living cells require minimally invasive methods. Optical tweezers are particularly attractive as a tool.

AZ, J&J tweaking COVID shots to reduce clotting risks; report

Pharma Phorum

AstraZeneca and Johnson & Johnson are both exploring ways to modify their COVID-19 vaccines to minimise the risk of severe blood clotting reactions that are seen – albeit rarely – in some people receiving the jabs.

Questions on new Alzheimer's drug benefit, price loom large at ICER meeting

Bio Pharma Dive

"Right now, and I think for a while, the access is going to be pretty limited," former CMS and FDA head Mark McClellan said at the meeting, which featured yet another rebuke by experts of Aduhelm

Drugs 221

ShapeTX Earns $112 Million Series B to Support Gene Therapy Development Projects


The amount is intended to support the company's growing portfolio of RNA technologies and accelerate efforts to develop various treatment approaches in the gene therapy field

RNA 94

Study shows that electronic air cleaning technology can generate unintended pollutants


Credit: Georgia Institute of Technology As the Covid-19 pandemic raged, news reports show that sales of electronic air cleaners have surged due to concerns about airborne disease transmission.

Sales 83

Aetion and Cegedim expand real-world data partnership

Pharma Times

In 2020, the two partners announced an initial collaboration to integrate Cegedim’s ‘THIN’ European real-world data into Aetion’s evidence platform